Google
Trusted Resources: News & Meetings
Latest announcements and gatherings
Amyloidosis now a hot topic in cardiac imaging due to new drug treatment
July 11, 2023 | Cardiovascular Business
For years, cardiac amyloidosis was a rare and often fatal disease that had no treatment, so it was not front and center in many cardiology conference sessions or discussions about cardiac imaging. However, that changed in May 2019 with the FDA clearance of the Pfizer drugs Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis), the first pharmaceutical treatments for amyloidosis. This helped lead to an explosion of interest in cardiology to screen for these cardiomyopathy patients so that they could be treated.
In the past four years, amyloidosis has come out of the shadows to the forefront of cardiology education as hospitals and clinics seek more information on how to image and test these patients. This is particularly important because not only is a diagnosis for amyloid needed, but the subtype also needs to be determined.
myBinderRelated Content
-
Rodney H. Falk, MDDr. Rodney H. Falk is the Director of th...
-
ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging In Cardiac Amyloido...Cardiac amyloidosis is a form of restric...
-
Novel Strategies for the Diagnosis and Treatment of Cardiac AmyloidosisSystemic amyloidoses are rare, complex d...
-
The University of Texas Southwestern Medical CenterThe University of Texas Southwestern Med...
-
Emerging treatment landscape for Cardiac Amyloidosishttps://www.pathlms.com/amyloidosis/webi...
-
Tafamidis Treatment of Transthyretin Mediated Amyloidosis (TTR) Approved by FDAhttps://www.youtube.com/watch?v=Bpzt6d6Q...
-
Cardiac Amyloidosis: An Update on Diagnosis and TreatmentCardiac amyloidosis (CA), once thought t...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Community Key Collaborator
Support for this landing page is provided by an independent education grant from
Translation of this platform made possible through an independent education grant from
Powered by
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
